2019 TOP 20 in the revenue of pharmaceutical companies - Generated the winner

With the financial reports of several major pharmaceutical companies in the world released in 2019, the industry media FiercePharm has made a ranking of TOP20 in the pharmaceutical field according to the revenue of each company in 2019.

2019 is a year of frequent acquisitions and reorganizations in the pharmaceutical field. BMS acquired Xinji and Takeda completed the acquisition of Shire. However, FiercePharm said that regardless of whether the company is M & A or restructuring, the top companies this time have good strengths in tumor research and development, and the fields of immunomedicine and rare diseases are also the focus areas of these companies.

In addition, in this ranking, several major pharmaceutical companies in the forefront of vaccine research and development have entered the top ten. Both Novartis and Roche's gene therapy have also continued to make progress.

Global healthcare giant Johnson & Johnson took the top spot with 2019 revenue of US $ 82.1 billion, of which pharmaceutical sales reached US $ 42.2 billion, an increase of 5.8% year-on-year, and medical equipment sales were US $ 29.63 billion, a year-on-year decrease of 1.7%.

Among the pharmaceutical revenues, ustinumab has become Johnson & Johnson's highest-selling drug, with sales up 25% from the previous year and reaching $ 6.3 billion. Another immunologic agent, Guseguzumab and multiple myeloma drugs Daretuzumab and Ibrutinib, also have significant growth. But at the same time, Abiraterone, whose Johnson's fist product is used to treat prostate cancer, is facing the impact of generic drugs on the market, and this trend will continue in 2020.

Roche ranked second in the list with revenue of US $ 63.54 billion in 2019.

In 2019, Roche's three best-selling drugs rituximab, bevacizumab and trastuzumab face the impact of biosimilar drugs. However, the explosive growth of its PD-L1 and hemophilia drug Hemlibrateb has brought a strong boost to its pharmaceutical sector. On the other hand, although Roche completed all antitrust approvals and successfully acquired Spark, it had previously worried the market about the prospect of large pharmaceutical companies acquiring biotech.

In 2019, Pfizer's total revenue was US $ 51.7 billion, a year-on-year decrease of 4%, ranking third in the ranking.

In 2019, Pfizer tried to divest low-margin products and focus on core products. The main measures include the merger of its general strong and generic drug giant Mylan to form a new company. In this process, Pfizer also emphasized its confidence in the growth of the core five products, including its profitable dairy cow pneumococcal vaccine-Peier. Pfizer is developing a 20-valent pneumococcal vaccine in order to be able to build on the 13-valent pneumococcal vaccine Increase the protection effect of 7 virus strains.

Novartis, ranked fourth, has a total revenue of USD 47.45 billion in 2019. In 2019, Novartis focused on innovative drugs, divested the eye care company Alcon, and acquired Xial, the ophthalmic drug of Shire. Novartis's heart failure drug Noxinto (Sacubatril Valsartan Sodium Tablets) achieved 2019 sales of US $ 1.73 billion, a year-on-year increase of 71%.

The growth of the revenue of major pharmaceutical companies depends on the promotion of major products. The K drug (pabolizumab), sitagliptin, and HPV vaccines successfully promoted sales growth of Merck, bringing the company's annual sales to 46.84 billion US dollars, ranking fifth in the ranking. The growth of GlaxoSmithKline in 2019 is largely due to the launch of the shingles vaccine. In 2019, this product created a revenue of 2.3 billion for GlaxoSmithKline, but at the same time, supply restrictions also restricted sales. Further growth.

BMS's two main products, Erlotux (apexaban tablets) and O-medicine (Navuliu monoclonal antibody), in 2019, sales exceeded US $ 7 billion, bringing BMS's 2019 sales revenue to US $ 26.15 billion. , An increase of 16% over the previous year, ranking 11th in the list.

During the new crown epidemic, Gilead was ranked 14th on the list with a revenue of 22.45 billion US dollars. Among them, HIV drug Bituwei contributed 4.74 billion US dollars in sales to the company, compared with 11.8 in the previous year. 100 million US dollars, an increase of up to 300%.

However, there seems to be more uncertainty in the drug sales market in 2020. The new crown epidemic has affected the sales of most drugs and devices, which will directly affect the company's sales revenue in 2020.

But the crisis is also a turning point. Many companies in the TOP20 have participated in the research and development competition for new crown drugs and vaccines. As mentioned in the FiercePharm article, the global economy is expecting pharmaceutical companies to give new coronavirus solutions. It is not difficult to imagine that once a company has a successful race, it will directly drive the company's revenue.